Compare Sun Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN SUN PHARMA/
LUPIN
 
P/E (TTM) x 76.1 40.5 187.9% View Chart
P/BV x 3.2 3.7 87.2% View Chart
Dividend Yield % 0.7 0.6 112.6%  

Financials

 SUN PHARMA   LUPIN
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
LUPIN
Mar-20
SUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs484882 54.9%   
Low Rs315505 62.4%   
Sales per share (Unadj.) Rs136.9339.4 40.3%  
Earnings per share (Unadj.) Rs17.5-5.9 -293.4%  
Cash flow per share (Unadj.) Rs26.015.5 168.1%  
Dividends per share (Unadj.) Rs4.006.00 66.7%  
Dividend yield (eoy) %1.00.9 115.7%  
Book value per share (Unadj.) Rs188.7276.7 68.2%  
Shares outstanding (eoy) m2,399.26453.00 529.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.0 142.9%   
Avg P/E ratio x22.9-116.6 -19.6%  
P/CF ratio (eoy) x15.444.8 34.3%  
Price / Book Value ratio x2.12.5 84.5%  
Dividend payout %22.9-100.9 -22.7%   
Avg Mkt Cap Rs m958,864314,201 305.2%   
No. of employees `00017.818.3 97.0%   
Total wages/salary Rs m63,62429,868 213.0%   
Avg. sales/employee Rs Th18,490.68,400.6 220.1%   
Avg. wages/employee Rs Th3,582.61,632.0 219.5%   
Avg. net profit/employee Rs Th2,357.6-147.2 -1,601.7%   
INCOME DATA
Net Sales Rs m328,375153,748 213.6%  
Other income Rs m6,3604,838 131.5%   
Total revenues Rs m334,735158,585 211.1%   
Gross profit Rs m69,89824,849 281.3%  
Depreciation Rs m20,5289,702 211.6%   
Interest Rs m3,0273,630 83.4%   
Profit before tax Rs m52,70216,355 322.2%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m-2,606-7,521 34.7%   
Tax Rs m8,22811,571 71.1%   
Profit after tax Rs m41,868-2,694 -1,554.2%  
Gross profit margin %21.316.2 131.7%  
Effective tax rate %15.670.8 22.1%   
Net profit margin %12.8-1.8 -727.7%  
BALANCE SHEET DATA
Current assets Rs m316,542154,132 205.4%   
Current liabilities Rs m157,06492,252 170.3%   
Net working cap to sales %48.640.2 120.7%  
Current ratio x2.01.7 120.6%  
Inventory Days Days8882 106.7%  
Debtors Days Days105129 81.0%  
Net fixed assets Rs m243,10289,082 272.9%   
Share capital Rs m2,399906 264.8%   
"Free" reserves Rs m450,245124,461 361.8%   
Net worth Rs m452,645125,367 361.1%   
Long term debt Rs m20,28917,933 113.1%   
Total assets Rs m682,525249,839 273.2%  
Interest coverage x18.45.5 334.4%   
Debt to equity ratio x00.1 31.3%  
Sales to assets ratio x0.50.6 78.2%   
Return on assets %6.60.4 1,755.9%  
Return on equity %9.2-2.1 -430.5%  
Return on capital %11.28.7 128.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m74,21951,450 144.3%   
Fx outflow Rs m27,96419,470 143.6%   
Net fx Rs m46,25531,980 144.6%   
CASH FLOW
From Operations Rs m65,54814,688 446.3%  
From Investments Rs m-25,88811,070 -233.9%  
From Financial Activity Rs m-57,151-8,906 641.7%  
Net Cashflow Rs m-13,85716,853 -82.2%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS